FrancophonIA/ELRC3.0 huggingface dataset:
English: In placebo-controlled clinical studies with background DMARDs, the frequency of opportunistic infections over 12/14 weeks in the upadacitinib 15 mg group was 0.5% compared to 0.3% in the placebo group.
Croatian: U placebom kontroliranim kliničkim ispitivanjima u kojima su bolesnici primali DMARD-ove kao osnovnu terapiju učestalost oportunističkih infekcija tijekom 12/14 tjedana iznosila je 0,5% u skupini liječenoj upadacitinibom u dozi od 15 mg te 0,3% u skupini koja je primala placebo.
English: SELECT BEYOND bDMARD-IR
Croatian: SELECT BEYOND Bolesnici s nedovoljno dobrim odgovorom na bDMARD
English: In the studies, a significantly higher proportion of patients treated with upadacitinib 15 mg achieved low disease activity (DAS28-CRP ≤3.2) and clinical remission (DAS28-CRP <2.6) compared to placebo, MTX or adalimumab (Table 4).
Croatian: U ispitivanjima je nisku aktivnost bolesti (DAS28-CRP ≤ 3,2) i kliničku remisiju (DAS28-CRP < 2,6)
English: • medicines to treat seizures or fits (such as phenytoin)
Croatian: • lijekove za liječenje napadaja (kao što je fenitoin)
English: • A reminder to use contraception, that upadacitinib is contraindicated during pregnancy, and to notify their HCPs if they become pregnant while taking upadacitinib o Description of signs/symptoms of deep venous thrombosis or pulmonary embolism which the patient needs to be aware of, so that they can seek attention from an HCP.
Croatian: • povišenja plazmatskih vrijednosti lipida te potrebu za njihovim praćenjem i primjenom lijekova za snižavanje vrijednosti lipida • podsjetnik da bolesnici moraju koristiti kontracepciju i da je upadacitinib kontraindiciran tijekom trudnoće te napomenu bolesnicama da obavijeste svog liječnika ako zatrudne tijekom liječenja upadacitinibom o opis znakova/simptoma duboke venske tromboze i plućne embolije s kojima bolesnik mora biti upoznat kako bi mogao potražiti liječničku pomoć
English: In MTX-controlled studies, the frequency of serious infection over 12/14 weeks in the upadacitinib 15 mg monotherapy group was 0.6% compared to 0.4% in the MTX group.
Croatian: U MTX-om kontroliranim ispitivanjima učestalost ozbiljnih infekcija tijekom 12/14 tjedana iznosila je 0,6% u skupini koja je primala monoterapiju upadacitinibom u dozi od 15 mg te 0,4% u skupini koja je primala MTX.
English: • you have recently had or plan to have a vaccination (immunisation) - this is because live vaccines are not recommended while using RINVOQ
Croatian: • ako ste nedavno primili ili trebate primiti neko cjepivo - naime, tijekom liječenja lijekom
English: MTX-Naїve
Croatian: MTX-oma
English: In clinical studies, treatment was interrupted in response to ANC < 1,000 cells/mm3 (see section 4.2).
Croatian: < 1000 stanica/mm3 (vidjeti dio 4.2).
English: In placebo-controlled clinical studies with background DMARDs, the frequency of serious infection over 12/14 weeks in the upadacitinib 15 mg group was 1.2% compared to 0.6% in the placebo group.
Croatian: U placebom kontroliranim kliničkim ispitivanjima u kojima su bolesnici primali DMARD-ove kao osnovnu terapiju učestalost ozbiljnih infekcija tijekom 12/14 tjedana iznosila je 1,2% u skupini liječenoj upadacitinibom u dozi od 15 mg te 0,6% u skupini koja je primala placebo.
English: Treatment with upadacitinib 15 mg, alone or in combination with csDMARDs, resulted in improvements in individual ACR components, including tender and swollen joint counts, patient and physician global assessments, HAQ-DI, pain assessment and hsCRP.
Croatian: Liječenje upadacitinibom u dozi od 15 mg u monoterapiji ili u kombinaciji s ksDMARD-ovima dovelo je do poboljšanja pojedinačnih sastavnica ACR odgovora, uključujući broj bolnih i otečenih zglobova,
English: In vitro, upadacitinib is a substrate for the efflux transporters P-gp and BCRP.
Croatian: In vitro je upadacitinib supstrat efluksnih prijenosnika P-glikoproteina (P-gp) i proteina rezistencije raka dojke (engl. breast cancer resistance protein, BCRP).
English: Malignancies were observed in clinical studies of upadacitinib.
Croatian: U kliničkim ispitivanjima upadacitiniba opažene su zloćudne bolesti.
English: Upadacitinib therapy should be interrupted if a patient develops a serious or opportunistic infection.
Croatian: Ako se u bolesnika razvije ozbiljna ili oportunistička infekcija, terapiju upadacitinibom treba privremeno prekinuti.
English: Adverse reactions System Organ Class
Croatian: Tablica 2: Nuspojave Organski sustav
English: Silica, colloidal anhydrous Magnesium stearate
Croatian: celuloza, mikrokristalična hipromeloza manitol tartaratna kiselina silicijev dioksid, koloidni, bezvodni magnezijev stearat
English: Prolonged-release tablet.
Croatian: Tabletu progutajte cijelu.
English: In a clinical study, rosuvastatin and atorvastatin AUC were decreased by 33% and 23%, respectively, and rosuvastatin Cmax was decreased by 23% following the administration of multiple 30 mg once daily doses of upadacitinib to healthy subjects.
Croatian: 33% odnosno 23%, dok se Cmax rosuvastatina smanjio za 23%.
English: • The Summary of Product Characteristics
Croatian: • Rezultat za tjelesnu komponentu upitnika
English: Intrinsic factors
Croatian: Ti učinci mogu
English: Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 15 mg of upadacitinib.
Croatian: Jedna tableta s produljenim oslobađanjem sadrži 15 mg upadacitiniba u obliku upadacitinib hemihidrata.
English: Evaluate at baseline and thereafter according to routine patient management.
Croatian: Vrijednosti jetrenih enzima treba utvrditi na početku liječenja, a zatim u skladu s rutinskim postupcima u sklopu liječenja bolesnika.
English: Screening for viral hepatitis and monitoring for reactivation should be performed before starting and during therapy with upadacitinib.
Croatian: Prije i tijekom liječenja upadacitinibom potrebno je provesti probir na virusni hepatitis i nadzirati bolesnike zbog moguće reaktivacije virusa.
English: SELECT-NEXT csDMARD-IRc
Croatian: SELECT-NEXT Bolesnici s nedovoljno dobrim odgovorom na ksDMARDc
English: AbbVie Logistics B.V Zuiderzeelaan 53
Croatian: AbbVie Logistics B.V.
English: Nausea
Croatian: Cijepljenje
English: Name and address of the manufacturers responsible for batch release
Croatian: PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET Nazivi i adrese proizvođača odgovornih za puštanje serije lijeka u promet
English: o Language on the risk of VTE during treatment with upadacitinib o Language on need for discontinuation of upadacitinib, evaluation, and appropriate treatment for VTE if clinical features of deep venous thrombosis or pulmonary embolism develop
Croatian: • informacije o riziku od VTE-a o primjere faktora rizika koji mogu povećati bolesnikov rizik od VTE-a i koji zahtijevaju oprez prilikom primjene upadacitiniba o informacije o riziku od VTE-a tijekom liječenja upadacitinibom o informacije o potrebi za prekidom primjene upadacitiniba te ocjenom bolesnika i uvođenjem odgovarajućeg liječenja za VTE u slučaju razvoja kliničkih znakova duboke venske tromboze ili plućne embolije
English: The risk of malignancies, including lymphoma is increased in patients with rheumatoid arthritis.
Croatian: U bolesnika s reumatoidnim artritisom povećan je rizik od zloćudnih bolesti, uključujući limfom.
English: hsCRP
Croatian: RMP-a
English: • you have cancer - because your doctor will have to decide if you can still be given RINVOQ
Croatian: RINVOQ ne preporučuje se primjena živih cjepiva • ako bolujete od raka - u tom će slučaju Vaš liječnik morati odlučiti možete li ipak uzimati
English: Talk to your doctor if you notice any of the following side effects: Very common (may affect more than 1 in 10 people)
Croatian: Vrlo česte (mogu se javiti u više od 1 na 10 osoba) • infekcije grla i nosa
English: • infection of the lung (pneumonia), which may cause shortness of breath, fever, and a cough with mucus
Croatian: • bolan kožni osip praćen mjehurićima (herpes zoster) • plućna infekcija (upala pluća) koja može uzrokovati nedostatak zraka, vrućicu i produktivan kašalj Navedene nuspojave javljaju se manje često (mogu se javiti u do 1 na 100 osoba).
English: How to store RINVOQ
Croatian: Moguće nuspojave Kako čuvati RINVOQ
English: • fever
Croatian: • vrućica • mučnina
English: Mean neutrophil counts decreased over 4 to 8 weeks.
Croatian: Srednje vrijednosti broja neutrofila opadale su tijekom
English: Patients should be monitored for changes in disease activity if upadacitinib is co-administered with strong CYP3A4 inducers.
Croatian: Ako se upadacitinib primjenjuje istodobno sa snažnim induktorima CYP3A4, bolesnike treba nadzirati zbog mogućih promjena u aktivnosti bolesti.
English: Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 15 mg upadacitinib
Croatian: Jedna tableta s produljenim oslobađanjem sadrži 15 mg upadacitiniba u obliku upadacitinib hemihidrata
English: Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with upadacitinib.
Croatian: • koji imaju podležeća stanja koja ih mogu učiniti podložnijima razvoju infekcije Tijekom i nakon liječenja upadacitinibom bolesnike treba pažljivo nadzirati zbog mogućeg razvoja znakova i simptoma infekcije.
English: Lorviqua is available as tablets (25 and 100 mg) and the recommended dose is 100 mg once a day.
Croatian: Lijek Lorviqua dostupan je u obliku tableta (25 i 100 mg), a preporučena doza je 100 mg jedanput dnevno.
English: There is more evidence to come about the medicine, which the company is required to provide.
Croatian: To znači da se očekuju dodatni podatci o lijeku koje tvrtka mora dostaviti.
English: Genetic defects affecting ALK (‘ALK-positive' status) should be confirmed in advance.
Croatian: Genetske nedostatke koji utječu na ALK (status „pozitivan na ALK”) potrebno je unaprijed potvrditi.
English: If certain side effects develop the doctor may reduce the dose or interrupt treatment temporarily.
Croatian: U slučaju razvoja određenih nuspojava liječnik može smanjiti dozu ili privremeno prekinuti liječenje.
English: Lorviqua must not be used together with medicines known as ‘strong CYP3A4/5 inducers' because the combined medicines could have an effect on the liver.
Croatian: Lorviqua se ne smije primjenjivati zajedno s lijekovima naziva „snažni induktori CYP3A4/5” jer kombinacija tih lijekova može utjecati na jetru.
English: Treatment may be stopped altogether if the patient develops severe side effects.
Croatian: Liječenje se može trajno obustaviti ako bolesnik razvije teške nuspojave.
English: It works by blocking the activity of ALK, thereby reducing the growth and spread of the cancer cells.
Croatian: Djeluje blokirajući aktivnost ALK-a, čime smanjuje rast i širenje stanica raka.
English: What measures are being taken to ensure the safe and effective use of Lorviqua?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Lorviqua?
English: Lorviqua has been given ‘conditional authorisation'.
Croatian: Za lijek Lorviqua izdano je „uvjetno odobrenje”.
English: The most common side effects with Lorviqua (which may affect more than 1 in 5 people) are hypercholesterolaemia (high blood cholesterol levels), hypertriglyceridaemia (high blood levels of triglycerides, a type of fat), oedema (build-up of fluid), peripheral neuropathy (nerve damage in the hands and feet), problems with thinking, learning and memory, tiredness, weight gain and effects on mood.
Croatian: Najčešće nuspojave lijeka Lorviqua (koje se mogu javiti u više od 1 na 5 osoba) su hiperkolesterolemija (visoke razine kolesterola u krvi), hipertrigliceridemija (visoke razine triglicerida, vrste masti), edem (nakupljanje tekućine), periferna neuropatija (oštećenja živaca na dlanovima i stopalima), problemi s razmišljanjem, učenjem i pamćenjem, umor, povećanje tjelesne težine i učinci na raspoloženje.
English: The European Medicines Agency therefore decided that Lorviqua's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove stoga je zaključila da koristi od lijeka Lorviqua nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
English: Response to treatment was assessed using body scans and standardised criteria for assessing solid tumours, with complete response being when the patient had no remaining signs of the cancer.
Croatian: Reakcija na liječenje ocijenjena je s pomoću snimanja tijela i standardiziranih kriterija koji se upotrebljavaju za solidne tumore, pri čemu je potpuni odgovor definiran kao nedostatak preostalih znakova raka u bolesnika.
English: What is Lorviqua and what is it used for?
Croatian: Što je Lorviqua i za što se primjenjuje?
English: Depending on which previous treatment the patients had received, around 67% and 52% of patients treated with Lorviqua had no signs of cancer in the brain or the signs of cancer had reduced.
Croatian: Ovisno o tome koju su terapiju bolesnici prethodno primili, oko 67 % i 52 % bolesnika liječenih lijekom Lorviqua nije pokazivalo znakove raka na mozgu ili su se znakovi raka smanjili.
English: Lorviqua received a conditional marketing authorisation valid throughout the EU on 6 May 2019 Further information on Lorviqua can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Lorviqua.
Croatian: Više informacija o lijeku Lorviqua nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Lorviqua.
English: Side effects reported with Lorviqua are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Lorviqua pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: ALK belongs to a family of enzymes called receptor tyrosine kinases, which are involved in the growth of cells and the development of new blood vessels that supply them.
Croatian: ALK pripada obitelji enzima naziva receptorske tirozin kinaze (RTK), koji su uključeni u rast stanica i razvoj novih krvnih žila koje ih opskrbljuju.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lorviqua have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Lorviqua nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: As for all medicines, data on the use of Lorviqua are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Lorviqua kontinuirano se prate.
English: Treatment with Lorviqua should be started and supervised by a doctor who is experienced in using cancer medicines.
Croatian: Terapiju lijekom Lorviqua mora započeti i nadzirati liječnik s iskustvom u primjeni lijekova protiv raka.
English: In this study Lorviqua was not compared with any other treatment or placebo (a dummy treatment).
Croatian: U oba ispitivanja lijek Lorviqua nije uspoređivan s drugim lijekom niti s placebom (prividnim liječenjem).
English: An overview of Lorviqua and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Lorviqua i zašto je odobren u EU-u
English: In addition, the company will provide the results of an ongoing study comparing Lorviqua with crizotinib in patients with ALK-positive NSCLC who have not been treated before.
Croatian: Nadalje, tvrtka će dostaviti rezultate ispitivanja koje je u tijeku, u kojem se uspoređuje Lorviqua s krizotinibom u bolesnika s NSCLC-om pozitivnim na ALK koji prethodno nisu liječeni.
English: Other information about Lorviqua
Croatian: Ostale informacije o lijeku Lorviqua
English: What are the risks associated with Lorviqua?
Croatian: Koji su rizici povezani s lijekom Lorviqua?
English: Lorviqua contains the active substance lorlatinib.
Croatian: Lorviqua sadrži djelatnu tvar lorlatinib.
English: Why is Lorviqua authorised in the EU?
Croatian: Zašto je lijek Lorviqua odobren u EU-u?
English: Lorviqua can only be obtained with a prescription.
Croatian: Lorviqua se izdaje samo na liječnički recept.
English: For more information about using Lorviqua, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Lorviqua pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: The active substance in Lorviqua, lorlatinib, is a tyrosine kinase inhibitor.
Croatian: Djelatna tvar u lijeku Lorviqua, lorlatinib, inhibitor je tirozin kinaze.
English: Since Lorviqua has been given conditional authorisation, the company that markets Lorviqua will conduct a study with the medicine in patients whose disease has worsened after treatment with alectinib or ceritinib.
Croatian: Kako je lijek Lorviqua dobio uvjetno odobrenje, tvrtka koja ga stavlja u promet provest će ispitivanje lijeka u bolesnika čija se bolest pogoršala nakon terapije alektinibom ili ceritinibom.
English: Out of patients who had been previously treated with crizotinib and another ALK tyrosine kinase inhibitor, around 40% had a complete or partial response to the medicine.
Croatian: Među bolesnicima koji su prethodno liječeni krizotinibom i drugim inhibitorom tirozin kinaze ALK, oko 40 % u potpunosti je ili djelomično reagiralo na lijek.
English: Lorviqua is a cancer medicine used to treat adults with non-small cell lung cancer (NSCLC), when the disease is advanced and ‘ALK-positive', which means that the cancer cells have certain changes affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).
Croatian: Lorviqua je lijek protiv raka koji se primjenjuje za liječenje odraslih s rakom nemalih stanica pluća (NSCLC-om) kad je bolest uznapredovala te je „pozitivna na ALK”, što znači da stanice raka imaju određene promjene koje djeluju na gen odgovoran za bjelančevinu naziva ALK (kinazu anaplastičnog limfoma).
English: Lorviqua was also effective against cancer that had spread to the brain.
Croatian: Lijek Lorviqua također je bio učinkovit kod raka koji se proširio na mozak.
English: In patients with ‘ALK-positive' NSCLC, an abnormal form of ALK is produced that causes the cancer cells to divide and grow in an uncontrolled fashion.
Croatian: U bolesnika s NSCLC-om pozitivnim na ALK stvara se abnormalni oblik ALK-a koji stimulira diobu i nekontrolirani rast stanica raka.
English: What information is still awaited for Lorviqua?
Croatian: Koje se još informacije očekuju o lijeku Lorviqua?
English: Lorviqua is used on its own when the disease has worsened despite treatment with other medicines of the same class known as ALK tyrosine kinase inhibitors (TKIs), including alectinib, ceritinib and crizotinib.
Croatian: Lorviqua se primjenjuje kao monoterapija kad se bolest pogoršala unatoč terapiji drugim lijekovima iz istog razreda poznatih pod nazivom inhibitori tirozin kinaze, uključujući alektinib, ceritinib i krizotinib.
English: How does Lorviqua work?
Croatian: Kako djeluje Lorviqua?
English: Lorviqua was effective at treating ALK-positive NSCLC in one main study which included 139 patients whose disease had worsened despite treatment with either alectinib or ceritinib or with crizotinib and another ALK tyrosine kinase inhibitor.
Croatian: Lijek Lorviqua pokazao se učinkovitim u liječenju NSCLC-a pozitivnog na ALK u jednom glavnom ispitivanju koje je uključivalo 139 bolesnika čija se bolest pogoršala usprkos terapiji alektinibom ili ceritinibom ili krizotinibom i drugim inhibitorom tirozin kinaze.
English: Around 43% of patients who had been previously treated with alectinib or ceritinib were considered by their doctors to have had a complete or partial response to the medicine.
Croatian: Liječnici su smatrali da je približno 43 % bolesnika prethodno liječenih alektinibom ili ceritinibom u potpunosti ili djelomično reagiralo na lijek.
English: What benefits of Lorviqua have been shown in studies?
Croatian: Koje su koristi od lijeka Lorviqua utvrđene u ispitivanjima?
English: Lorviqua is effective at treating ALK-positive NSCLC that has worsened despite treatment with other ALK tyrosine kinase inhibitors.
Croatian: Lijek Lorviqua učinkovit je u liječenju NSCLC-a pozitivnog na ALK koji se pogoršao usprkos terapiji drugim inhibitorima tirozin kinaze ALK.
English: For the full list of side effects and restrictions with Lorviqua, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Lorviqua potražite u uputi o lijeku.
English: How is Lorviqua used?
Croatian: Kako se Lorviqua primjenjuje?
English: Very few other treatments are available for patients after ALK tyrosine kinase inhibitors have failed or for those whose cancer has spread to the brain, and the side effects with Lorviqua are manageable.
Croatian: Bolesnici u kojih inhibitori ALK tirozin kinaze nisu djelovali ili čiji se rak proširio na mozak imaju su vrlo ograničene mogućnosti drugih terapija, a nuspojave lijeka Lorviqua može se kontrolirati.
English: Pack size blister (PA/Alu/PVC/Alu)
Croatian: Veličina pakovanja blister (PA/Alu/PVC/A lu)
English: 240 capsules
Croatian: 240 kapsula
English: 224 (4 x 56) capsules
Croatian: 224 (4 x 56) kapsula
English: Use in adults, including the elderly
Croatian: Primjena kod odraslih, uključujući starije
English: • Make sure you have a mirror available.
Croatian: • Provjerite imate li dostupno ogledalo.
English: • if you have severe hay fever.
Croatian: • ako imate tešku peludnu groznicu.
English: Raynaud's phenomenon, cold hands and feet
Croatian: Raynaudov fenomen, hladne ruke i stopala
English: It should be administered at the same time each day.
Croatian: Mora biti primijenjen u isto vrijeme svaki dan.
English: Ask your pharmacist how to throw away medicines you longer use.
Croatian: Pitajte svog ljekarnika kako baciti lijekove koje više ne koristite.
English: However, this effect was not observed during the clinical trials and is considered to be species specific.
Croatian: Ovaj učinak, međutim, nije primijećen za vrijeme kliničkih ispitivanja te se smatra specifičnim za vrstu.
English: Use at the same time each day.
Croatian: Uvijek primjenjujte u isto vrijeme svaki dan.
English: The response of these patients should be closely observed.
Croatian: Reakciju ovih bolesnika je potrebno pomno pratiti.
English: Do not open the overwrap until you need to use the bottle.
Croatian: Ne otvarajte zaštitni omot sve dok ne trebate otvoriti bočicu.
English: No dose adjustment was necessary in these patients.
Croatian: Nije bilo potrebno prilagođavati dozu u ovih bolesnika.
English: • If you have to use DuoTrav in both eyes, repeat the above steps for your other eye.
Croatian: • Ako trebate primjeniti DuoTrav u oba oka, ponovite gornje korake na drugom oku.
English: It is therefore important to tell the doctor that you are using DuoTrav when you are to receive any other treatment.
Croatian: Stoga je važno reći liječniku da primjenjujete DuoTrav kada primate bilo kakvu drugu terapiju.
English: Seasonal allergy
Croatian: Sezonska alergija
English: The safety and efficacy of DuoTrav in children and adolescents below the age of 18 years have not been established.
Croatian: Sigurnost i djelotvornost DuoTrava u djece i adolescenata ispod 18 godina nije ustanovljena.
English: Additionally:
Croatian: Dodatno:
English: • if the surface of your eye is cloudy.
Croatian: • ako je površina Vašeg oka zamućena.
English: You must throw away the bottle 4 weeks after you first opened it to prevent the risk of infections.
Croatian: Bočicu morate baciti 4 tjedna nakon prvog otvaranja da bi se spriječio rizik od infekcija.
English: They are ranked according to system organ class and classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data).
Croatian: Razvrstane su prema klasifikaciji organskih sustava i klasificirane su prema slijedećem dogovoru: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).